The emergence of dual-action receptor agonists in the treatment of type 2 diabetes and obesity has sparked considerable focus, particularly regarding retatrutide and tirzepatide. While both medications target both the https://loriatxn105025.daneblogger.com/37632379/retatrutide-vs-tirzepatide-a-comparative-analysis